JP2014533259A - カリウムチャネル阻害剤として有用なチエノおよびフロピリミジンならびにピリジン - Google Patents

カリウムチャネル阻害剤として有用なチエノおよびフロピリミジンならびにピリジン Download PDF

Info

Publication number
JP2014533259A
JP2014533259A JP2014540560A JP2014540560A JP2014533259A JP 2014533259 A JP2014533259 A JP 2014533259A JP 2014540560 A JP2014540560 A JP 2014540560A JP 2014540560 A JP2014540560 A JP 2014540560A JP 2014533259 A JP2014533259 A JP 2014533259A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
thieno
pyrimidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014540560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533259A5 (enExample
Inventor
マッジ デービッド
マッジ デービッド
チャン フィオナ
チャン フィオナ
エドワード ジョン デレク
エドワード ジョン デレク
ディー エドワーズ サイモン
ディー エドワーズ サイモン
ブラント リチャード
ブラント リチャード
ハートゾウラキス バジル
ハートゾウラキス バジル
ブラウン リンジー
ブラウン リンジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xention Ltd
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1119703.5A external-priority patent/GB201119703D0/en
Priority claimed from GBGB1214250.1A external-priority patent/GB201214250D0/en
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of JP2014533259A publication Critical patent/JP2014533259A/ja
Publication of JP2014533259A5 publication Critical patent/JP2014533259A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2014540560A 2011-11-15 2012-11-15 カリウムチャネル阻害剤として有用なチエノおよびフロピリミジンならびにピリジン Pending JP2014533259A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1119703.5A GB201119703D0 (en) 2011-11-15 2011-11-15 Compounds
GB1119703.5 2011-11-15
GB1214250.1 2012-08-09
GBGB1214250.1A GB201214250D0 (en) 2012-08-09 2012-08-09 Compounds
PCT/GB2012/052842 WO2013072694A1 (en) 2011-11-15 2012-11-15 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors

Publications (2)

Publication Number Publication Date
JP2014533259A true JP2014533259A (ja) 2014-12-11
JP2014533259A5 JP2014533259A5 (enExample) 2016-01-14

Family

ID=47222145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540560A Pending JP2014533259A (ja) 2011-11-15 2012-11-15 カリウムチャネル阻害剤として有用なチエノおよびフロピリミジンならびにピリジン

Country Status (15)

Country Link
US (2) US9290511B2 (enExample)
EP (1) EP2780343A1 (enExample)
JP (1) JP2014533259A (enExample)
KR (1) KR20140094603A (enExample)
CN (1) CN104011054B (enExample)
AR (1) AR090037A1 (enExample)
AU (1) AU2012338570A1 (enExample)
BR (1) BR112014011671A2 (enExample)
CA (1) CA2855346A1 (enExample)
IN (1) IN2014MN01183A (enExample)
MX (1) MX2014005935A (enExample)
RU (1) RU2014124101A (enExample)
TW (1) TWI498331B (enExample)
WO (1) WO2013072694A1 (enExample)
ZA (1) ZA201403503B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522856A (ja) * 2015-06-23 2018-08-16 レ ラボラトワール セルヴィエ 新規なアミノ酸誘導体、その製造方法、及びそれを含有する医薬組成物
JP2018522855A (ja) * 2015-06-23 2018-08-16 レ ラボラトワール セルヴィエ 新規なヒドロキシエステル誘導体、その調製方法及びそれを含有する医薬組成物
JP2018527297A (ja) * 2015-06-23 2018-09-20 レ ラボラトワール セルヴィエ 新規な二環式誘導体、それらを調製するためのプロセス及びそれらを含有する医薬組成物
JP2018527296A (ja) * 2015-06-23 2018-09-20 レ ラボラトワール セルヴィエ 新規なヒドロキシ酸誘導体、その製造方法、及びそれを含有する医薬組成物
JP2023512113A (ja) * 2019-11-29 2023-03-23 大鵬薬品工業株式会社 Ｋｒａｓ ｇ１２ｄ変異に対して阻害活性を有する化合物
JP2024511101A (ja) * 2021-03-22 2024-03-12 アセシオン ファーマ エイピーエス 新規カリウムチャネル阻害剤
JP2024518000A (ja) * 2021-04-30 2024-04-23 ヴァンキア バイオ，インコーポレイテッド グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509989VA (en) 2013-06-06 2016-01-28 Astellas Pharma Inc Benzothiophene compound
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2545758C1 (ru) * 2014-03-20 2015-04-10 Общество с ограниченной ответственностью "Алион" Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
EP3668841B1 (en) * 2017-08-14 2026-07-08 Acesion Pharma Aps Substituted benzimidazoles as potassium channel inhibitors
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
CN108117556A (zh) * 2018-01-15 2018-06-05 王山川 一种细胞周期检查点激酶1抑制剂的合成方法
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
WO2022194191A1 (en) * 2021-03-16 2022-09-22 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12d
JP2024511801A (ja) * 2021-03-26 2024-03-15 スミトモ ファーマ オンコロジー， インコーポレイテッド （フロピリミジン－４－イル）ピペラジン化合物及びその使用
CN115006468B (zh) * 2022-06-28 2023-06-06 西安外事学院 一种复方中草药生发液及制备方法
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014850A2 (en) * 2002-08-08 2004-02-19 Predix Pharmaceuticals Holdings, Inc. Substituted aminopyrimidines as neurokinin antagonists
WO2004065391A1 (en) * 2003-01-23 2004-08-05 Almirall Prodesfarma S.A. 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS
WO2004111057A1 (en) * 2003-06-11 2004-12-23 Xention Discovery Limited Thienopyrimidine derivatives as potassium channel inhibitors
WO2005100365A1 (ja) * 2004-04-12 2005-10-27 Sankyo Company, Limited チエノピリジン誘導体
WO2005121149A1 (en) * 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
WO2006061642A1 (en) * 2004-12-09 2006-06-15 Xention Discovery Limited Compounds
WO2006135639A1 (en) * 2005-06-10 2006-12-21 Janssen Pharmaceutica N.V. Thiξnopyrimidine and thienopyridine derivatives as flt-3 kinase inhibitors
WO2007066127A2 (en) * 2005-12-09 2007-06-14 Xention Limited Thieno ( 3 , 2-c) pyridine compounds
WO2007146284A2 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en) * 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
WO1998008845A1 (en) 1996-08-27 1998-03-05 Novartis Ag Herbicidal s-substituted 1,2,4,6-thiatriazines
WO2004011057A1 (en) 1998-02-07 2004-02-05 Advanced Cardiovascular Systems, Inc. Perfusion dilatation catherer with expanded support coil
JP2001097979A (ja) 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
WO2001021610A1 (en) 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10031585A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-Aminoalkyl-thieno[2,3-d]pyrimidine
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
IL159218A0 (en) 2001-06-25 2004-06-01 Nissan Chemical Ind Ltd Substituted benzopyran derivatives against arrhythmia
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US7594219B2 (en) 2003-07-24 2009-09-22 International Business Machines Corporation Method and apparatus for monitoring compatibility of software combinations
TWI346112B (en) 2004-02-25 2011-08-01 Nissan Chemical Ind Ltd Benzopyran compound
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006047397A1 (en) 2004-10-21 2006-05-04 Dow Agrosciences Llc Thieno-pyrimidine compounds having fungicidal activity
US7576212B2 (en) * 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
CA2595882A1 (en) 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
WO2006100591A1 (en) 2005-03-25 2006-09-28 Pharmacia & Upjohn Company Llc 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
EP1896483A2 (en) 2005-03-28 2008-03-12 Pharmacia & Upjohn Company LLC 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602538A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602227A1 (en) 2005-03-28 2006-10-05 Michael Dalton Ennis 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
AU2006261082B2 (en) * 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
US7816351B2 (en) * 2005-09-23 2010-10-19 Equispharm Co., Ltd 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
DE102006030236A1 (de) 2006-06-30 2008-01-03 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Direktoxidationsbrennstoffzelle für den konvektionsfreien Transport des Brennstoffs und Verfahren zum Betreiben der Brennstoffzelle
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TW200924781A (en) * 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
PL2254873T3 (pl) 2008-02-22 2014-10-31 Otsuka Pharma Co Ltd Związek benzodiazepinowy i kompozycja farmaceutyczna
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
BRPI0918971A2 (pt) * 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
TWI334124B (en) * 2008-08-28 2010-12-01 Au Optronics Corp Display drive circuit for flat panel display and driving method for gate lines
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
AR073739A1 (es) 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
WO2010033127A1 (en) 2008-09-22 2010-03-25 Sionyx, Inc. Response-enhanced monolithic-hybrid pixel
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
JP5619907B2 (ja) 2009-10-29 2014-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物
CA2788450A1 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
TW201219401A (en) * 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014850A2 (en) * 2002-08-08 2004-02-19 Predix Pharmaceuticals Holdings, Inc. Substituted aminopyrimidines as neurokinin antagonists
WO2004065391A1 (en) * 2003-01-23 2004-08-05 Almirall Prodesfarma S.A. 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS
WO2004111057A1 (en) * 2003-06-11 2004-12-23 Xention Discovery Limited Thienopyrimidine derivatives as potassium channel inhibitors
WO2005100365A1 (ja) * 2004-04-12 2005-10-27 Sankyo Company, Limited チエノピリジン誘導体
WO2005121149A1 (en) * 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
WO2006061642A1 (en) * 2004-12-09 2006-06-15 Xention Discovery Limited Compounds
WO2006135639A1 (en) * 2005-06-10 2006-12-21 Janssen Pharmaceutica N.V. Thiξnopyrimidine and thienopyridine derivatives as flt-3 kinase inhibitors
WO2007066127A2 (en) * 2005-12-09 2007-06-14 Xention Limited Thieno ( 3 , 2-c) pyridine compounds
WO2007146284A2 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5015000625; ＨＯＺＩＥＮ　Ｚ　Ａ: 'ＳＹＮＴＨＥＳＩＳ　ＡＮＤ　ＡＰＰＬＩＣＡＴＩＯＮ　ＯＦ　ＳＯＭＥ　ＮＥＷ　ＴＨＩＥＮＯＰＹＲＩＭＩＤＩＮＥ　ＤＥＲＩＶＡＴＩＶＥＳ　ＡＳ　ＡＮＴＩＭＩＣＲＯＢＩＡＬ　ＡＧＥＮＴＳ' ＳＹＮＴＨＥＴＩＣ　ＣＯＭＭＵＮＩＣＡＴＩＯＮＳ Ｖｏｌ．２６　Ｎｏ．２０, 19960101, ｐ．３７３３-５５, ＴＡＹＬＯＲ　＆　ＦＲＡＮＣＩＳ　ＩＮＣ． *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522856A (ja) * 2015-06-23 2018-08-16 レ ラボラトワール セルヴィエ 新規なアミノ酸誘導体、その製造方法、及びそれを含有する医薬組成物
JP2018522855A (ja) * 2015-06-23 2018-08-16 レ ラボラトワール セルヴィエ 新規なヒドロキシエステル誘導体、その調製方法及びそれを含有する医薬組成物
JP2018527297A (ja) * 2015-06-23 2018-09-20 レ ラボラトワール セルヴィエ 新規な二環式誘導体、それらを調製するためのプロセス及びそれらを含有する医薬組成物
JP2018527296A (ja) * 2015-06-23 2018-09-20 レ ラボラトワール セルヴィエ 新規なヒドロキシ酸誘導体、その製造方法、及びそれを含有する医薬組成物
JP2023512113A (ja) * 2019-11-29 2023-03-23 大鵬薬品工業株式会社 Ｋｒａｓ ｇ１２ｄ変異に対して阻害活性を有する化合物
JP7707189B2 (ja) 2019-11-29 2025-07-14 大鵬薬品工業株式会社 Ｋｒａｓ ｇ１２ｄ変異に対して阻害活性を有する化合物
JP2024511101A (ja) * 2021-03-22 2024-03-12 アセシオン ファーマ エイピーエス 新規カリウムチャネル阻害剤
JP7853995B2 (ja) 2021-03-22 2026-04-30 アセシオン ファーマ エイピーエス 新規カリウムチャネル阻害剤
JP2024518000A (ja) * 2021-04-30 2024-04-23 ヴァンキア バイオ，インコーポレイテッド グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用

Also Published As

Publication number Publication date
KR20140094603A (ko) 2014-07-30
NZ626199A (en) 2015-04-24
AR090037A1 (es) 2014-10-15
US9290511B2 (en) 2016-03-22
TWI498331B (zh) 2015-09-01
MX2014005935A (es) 2014-09-04
TW201326178A (zh) 2013-07-01
BR112014011671A2 (pt) 2017-05-30
US20160152634A1 (en) 2016-06-02
ZA201403503B (en) 2016-09-28
US20140371203A1 (en) 2014-12-18
CN104011054B (zh) 2016-08-24
CN104011054A (zh) 2014-08-27
IN2014MN01183A (enExample) 2015-07-03
AU2012338570A1 (en) 2014-07-03
WO2013072694A1 (en) 2013-05-23
CA2855346A1 (en) 2013-05-23
EP2780343A1 (en) 2014-09-24
RU2014124101A (ru) 2015-12-27

Similar Documents

Publication Publication Date Title
CN104011054B (zh) 用作钾通道抑制剂的噻吩并和呋喃并嘧啶类和吡啶类
WO2023066350A1 (zh) Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
TWI801156B (zh) 作為纖維母細胞生長因子受體抑制劑之經取代三環化合物
JP4719317B2 (ja) 縮合複素環誘導体およびその用途
EP2943485B1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
JP2023530320A (ja) Ｎａｖ１．８阻害剤としての５－オキソピロリジン－３－カルボキサミド
KR102517352B1 (ko) Nik 억제제로서의 헤테로방향족 유도체
CN104755083B (zh) 氨基烷基哌嗪的脲和酰胺衍生物及其用途
JP2008514643A (ja) 新規ピペリジニルアミノ−チエノ［２，３−ｄ］ピリミジン化合物
TWI843949B (zh) 黑皮質素4(melanocortin 4)受體拮抗劑及其用途
KR20180014433A (ko) 핵 수용체 조절제
US20170334907A1 (en) Bicyclic heterocycle compounds and their uses in therapy
JP7716777B2 (ja) 窒素含有多環式縮合環系化合物、その医薬組成物、製造方法及び用途
KR20180100441A (ko) Nik 억제제로서 신규 치환된 시아노인돌린 유도체
KR20160086404A (ko) Mknk1 및 mknk2 억제제로서의 티에노피리미딘
TWI869674B (zh) 雜芳基衍生化合物及其用途
US20250214989A1 (en) Naphthyridinone derivatives for the treatment of a disease or disorder
JP2014533258A (ja) カリウムチャネル阻害剤としてのチエノ［２，３−ｃ］ピラゾールの使用
US20240391941A1 (en) Naphthyridinone derivatives for the treatment of a disease or disorder
JP2002504883A (ja) コリン受容体リガンドとしての７−アザビシクロ［２．２．１］−ヘプタン及び−ヘプテン誘導体
NZ626199B2 (en) Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors
OA21024A (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151116

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20151116

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20151208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170228